Precision medicine
The company will use the funds to enrich its technology, commercialize its MRD product and continue the development of its multi-cancer early detection offering.
Medicare-focused virtual exercise platform Bold secured $17 million.
The pair will work to further the practice of radiology and patient care using innovation, such as theranostics, AI and digital health platforms.
The multiple sclerosis-focused company will use the funds to speed up the company's commercialization efforts.
The funding comes three months after the company announced it added AI-enabled imaging features and new indications expanding xvision's use to the whole spine.
At HIMSS23, panelists discussed how genomics could improve patient care and the challenges to implementing genetic testing programs.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Elena Viboch, partner at General Catalyst, discusses her predictions for biotech and health tech investing and how startups can grow in a more constrained economic environment.
The AI-backed genomic and clinical data company announced it had laid off about 250 workers in August.
The multinational pharma company will now be able to access Tempus' de-identified patient data.